2009-11-10 15:04:01 -

BioClinica™, Inc., (NASDAQ: BIOC), a global provider of clinical trial services, today announced it will be hosting a seminar on November 18, 2009 highlighting new research, trends and updates from industry experts in rheumatoid arthritis. This event, which will be held in Lafayette, PA, is part of the continuing series of symposia hosted by the company for pharmaceutical and medical imaging executives over the past four years that addresses the challenges and approaches in conducting clinical trials.

Rheumatoid arthritis studies in Phase III trials generally rely on radiographs to determine the imaging endpoints. In addition, MRI has become an essential imaging modality for the assessment of rheumatoid arthritis patients, particularly in the Phase II setting. BioClinica has helped support image collection

and central reads in clinical trials for five separate FDA-approved therapeutic agents for the treatment of rheumatoid arthritis, all of which are currently being marketed and used worldwide.

“BioClinica understands the critical level of detail that is required to ensure success in rheumatoid arthritis clinical trials,” said Mark L.

Weinstein, President and CEO of BioClinica. “RA is one of several key therapeutic areas in which we have project management teams dedicated only to that specialty. This model ensures that our clients obtain the knowledge, expertise and talent that will help their trial to succeed, and it increases the efficiency and success of their clinical trials programs, from start-up to submission.”

BioClinica is an industry leader in supporting international multi-center clinical trials in the therapeutic areas of oncology, cardiology, neurology, and musculoskeletal diseases, including rheumatoid arthritis, osteoporosis and osteoarthritis. The company’s therapeutically-specialized project management teams coordinate all functions of the medical image data management. Each team includes scientific and medical staff, a network of world-renowned key opinion leaders and an extensive roster of collaborative consultants. With experience gained in more than 800 imaging studies of all sizes, these experts can help to maximize the efficiency and quality of any therapeutic clinical trial.


Symposium Details

Focusing on “Medical Imaging for Rheumatoid Arthritis in Clinical Trials – Successful Trial Design and Delivery,” the symposium will be a series of presentations with discussions on relevant topics, including.

- Designing a Successful Radiographic
- MRI Scoring
- Campaign Designs
- Handling of Missing Information
- Evaluating and Interpreting Mock Read Results


Valuable insight on these topics will be delivered by industry leaders, including.

- Désirée van der Heijde, MD, Ph.D., Professor of Rheumatology, Leiden University Medical Center, Imaging Rheumatology, BV, Leiden, Netherlands
- Robert Landewé, MD, Ph.D., Professor of Rheumatology, University Hospital, Maastricht, Maastricht, Netherlands
- Ali Guermazi, MD, Section Chief, Musculoskeletal Director, Quantitative Imaging Center (QIC), Department of Radiology, Boston University Medical Center


The event will be held at the ACE Conference Center in Lafayette PA, starting at 8:00 a.m. EST on November 18, 2009. Pharmaceutical and device company personnel, medical imaging executives, and partners are invited to attend this complementary symposium. For more details, please visit.

www.bioclinica.com/rheumatoid-arthritis-symposium : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. .


About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial services. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, and clinical supply chain design and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States and Europe. For more information, please visit www.bioclinica.com : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. .

Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.
You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

BioClinica, Inc.Jim Dorsey, 267-757-3040orPorter,
LeVay & Rose, Inc.Investors:Linda Decker,

212-564-4700orFinancial Media:Bill Gordon, 212-564-4700orDiccicco
Battista CommunicationsTrade Media:Brian Gawron,

215-957-0300